Deal snapshot: AbbVie joins peers Merck & Co., Roche and Pfizer with a TL1A-targeted antibody for potential therapy in inflammatory bowel disease, paying $150m up front.

Keytruda brought in its usual stacks of cash, but Merck’s Q3 earnings call focused largely on a recent alliance with Daiichi Sankyo and the pharma’s growing emphasis on cancer ADCs.

Pfizer gave US rights to an asset to Roivant, which turned around and sold it to Roche for $7.1bn 10 months later. Pfizer says it’s content with the 25% stake it will receive. Roivant CEO Matt Gline also talked to Scrip about the sudden turnaround. 

Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.